Cargando…

Beta variant COVID-19 protein booster vaccine elicits durable cross-neutralization against SARS-CoV-2 variants in non-human primates

The rapid spread of the SARS-CoV-2 Omicron subvariants, despite the implementation of booster vaccination, has raised questions about the durability of protection conferred by current vaccines. Vaccine boosters that can induce broader and more durable immune responses against SARS-CoV-2 are urgently...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pavot, Vincent, Berry, Catherine, Kishko, Michael, Anosova, Natalie G., Li, Lu, Tibbitts, Tim, Huang, Dean, Raillard, Alice, Gautheron, Sylviane, Gutzeit, Cindy, Koutsoukos, Marguerite, Chicz, Roman M., Lecouturier, Valerie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998256/ https://www.ncbi.nlm.nih.gov/pubmed/36894558 http://dx.doi.org/10.1038/s41467-023-36908-z

Ejemplares similares

Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates
por: Pavot, Vincent, et al.
Publicado: (2022)

Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters
por: Berry, Catherine, et al.
Publicado: (2023)

Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model
por: Kalnin, Kirill V., et al.
Publicado: (2022)

The potential of Beta variant containing COVID booster vaccines for chasing Omicron in 2022
por: Sridhar, Saranya, et al.
Publicado: (2022)

Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates
por: Francica, Joseph R., et al.
Publicado: (2021)

Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination
por: Yu, Xiaoqi, et al.
Publicado: (2022)

mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
por: Gruell, Henning, et al.
Publicado: (2022)

Extensive neutralization against SARS-CoV-2 variants elicited by Omicron-specific subunit vaccine as a heterologous booster
por: Peng, Pai, et al.
Publicado: (2022)

An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults
por: Li, Tao, et al.
Publicado: (2023)

Immunity against Delta and Omicron variants elicited by homologous inactivated vaccine booster in kidney transplant recipients
por: Zhang, Lei, et al.
Publicado: (2023)

Omicron variant of SARS-CoV-2 infection elicits cross-protective immunity in people who received boosters or infected with variant strains
por: Chowdhury, Selia, et al.
Publicado: (2022)

A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants
por: Lam, Joy-Yan, et al.
Publicado: (2022)

A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates
por: Weidenbacher, Payton A.-B., et al.
Publicado: (2022)

A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates
por: Weidenbacher, Payton A.-B., et al.
Publicado: (2023)

Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant
por: Zhao, Xin, et al.
Publicado: (2022)

SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum, but evades most convalescent serum and therapeutic antibodies
por: Lusvarghi, Sabrina, et al.
Publicado: (2022)

Omicron variants breakthrough infection elicited higher specific memory immunity than third dose booster in healthy vaccinees
por: Yu, Pei, et al.
Publicado: (2023)

Limited cross-variant neutralization after primary Omicron infection: consideration for a variant-containing booster
por: Marcotte, Harold, et al.
Publicado: (2022)

Durability of Bivalent Boosters against Omicron Subvariants
por: Lin, Dan-Yu, et al.
Publicado: (2023)

A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern
por: Lee, I-Jung, et al.
Publicado: (2022)

Author Correction: A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates
por: Weidenbacher, Payton A.-B., et al.
Publicado: (2023)

Inversion variants in human and primate genomes
por: Catacchio, Claudia Rita, et al.
Publicado: (2018)

Durability of the Neutralizing Antibody Response to mRNA Booster Vaccination Against SARS-CoV-2 BA.2.12.1 and BA.4/5 Variants
por: Qu, Panke, et al.
Publicado: (2022)

Omicron variant and booster COVID-19 vaccines
por: Burki, Talha Khan
Publicado: (2022)

COVID vaccine booster doses for omicron variants
por: Burki, Talha
Publicado: (2022)

Covid-19 Vaccines — Immunity, Variants, Boosters
por: Barouch, Dan H.
Publicado: (2022)

Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain
por: Takano, Tomohiro, et al.
Publicado: (2023)

A pan-sarbecovirus vaccine induces highly potent and durable neutralizing antibody responses in non-human primates against SARS-CoV-2 Omicron variant
por: Liu, Zezhong, et al.
Publicado: (2022)

Could Beta variant containing COVID-19 booster vaccines tackle Omicron variants?
por: Jin, Pengfei, et al.
Publicado: (2023)

Delta breakthrough infections elicit potent, broad and durable neutralizing antibody responses
por: Walls, Alexandra C., et al.
Publicado: (2021)

Omicron variant: a booster depending on infection histories
por: Wang, Jiayu, et al.
Publicado: (2023)

saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern
por: Komori, Mai, et al.
Publicado: (2023)

COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer
por: Zeng, Cong, et al.
Publicado: (2022)

Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant
por: Zuo, Fanglei, et al.
Publicado: (2022)

Effectiveness of mRNA booster doses against the omicron variant
por: Zedan, Hadeel T, et al.
Publicado: (2022)

Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study
por: de Bruyn, Guy, et al.
Publicado: (2023)

Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates
por: Francica, Joseph R., et al.
Publicado: (2021)

An optimized purified inactivated Zika vaccine provides sustained immunogenicity and protection in cynomolgus macaques
por: Lecouturier, Valérie, et al.
Publicado: (2020)

Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines
por: Dubé, Charlotte, et al.
Publicado: (2022)

Third booster vaccination and stopping the Omicron, a new variant of concern
por: Ghazvini, Kiarash, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8pglppegm5bt7k3a5sfhgefld2